Search company, investor...
Novome Biotechnologies company logo

Novome Biotechnologies

Founded Year



Series B | Alive

Total Raised


Last Raised

$43.5M | 6 mos ago

About Novome Biotechnologies

Novome Biotechnologies is a therapeutics company engineering bacteria to treat gastrointestinal diseases. Its product includes Genetically Engineered Microbial Medicines (GEMMs), a platform for the controlled colonization of the gut with engineered bacteria to deliver targeted therapeutic cargos and functions. The company was founded in 2015 and is based in South San Francisco, California.

Headquarters Location

279 E Grand Ave Suite 420

South San Francisco, California, 94080,

United States


Missing: Novome Biotechnologies's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Novome Biotechnologies's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Novome Biotechnologies

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Novome Biotechnologies is included in 3 Expert Collections, including Synthetic Biology.


Synthetic Biology

238 items

Companies involved in design and development of new biological parts, devices, and systems; as well as the re-design of existing biological systems.



275 items


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Novome Biotechnologies Patents

Novome Biotechnologies has filed 8 patents.

The 3 most popular patent topics include:

  • Bacteriology
  • Microbiology
  • Molecular biology
patents chart

Application Date

Grant Date


Related Topics




Bacteriology, Microbiology, Microbiomes, Bacteria, Molecular biology


Application Date


Grant Date



Related Topics

Bacteriology, Microbiology, Microbiomes, Bacteria, Molecular biology



Latest Novome Biotechnologies News

Novome Biotechnologies raises $43.5M for therapeutically engineered microbes pipeline

Sep 15, 2022

Photo/Shutterstock U.S. biotech company Novome Biotechnologies, Inc., has closed a $43.5 million series B financing round. The financing was led by Tencent, and includes new investors University of Minnesota, Navian Investments, Colorcon Ventures and Touchdown Ventures. Existing investors DCVC Bio, 5AM Ventures, Alta Partners and Alexandria Venture Investments also participated. The proceeds will be used to advance both Novome’s clinical hyperoxaluria candidate, NOV-001, through an ongoing phase 2a clinical trial, and multiple genetically engineered microbial medicines (GEMMs) candidates for the potential treatment of inflammatory bowel disease (IBD). Candidates are either fully owned by Novome or part of a previously announced collaboration with Genentech. “Our team has made tremendous progress this year, including initiation of the phase 2a portion of the enteric hyperoxaluria clinical trial of NOV-001 and advancing our platform capabilities, most notably developing the ability for our oral GEMMs to deliver high amounts of therapeutic proteins to the gastrointestinal tract through continuous, controlled secretion,” said Blake Wise, CEO of Novome. “Novome’s recent accomplishments and this new funding should further advance and validate our platform’s capabilities and unlock additional pipeline opportunities. I am grateful for the strong support of new and current investors who share our vision of developing first-in-class therapeutically engineered gut microbes.” Phase 2a clinical trial The ongoing phase 2a clinical trial is the second stage of the NOV-001 phase 1/2a program. Results from the phase 1 stage were reported late last year and demonstrated the ability to safely colonize the human gut with a therapeutically engineered microbe and control its abundance via once-daily dosing of a prebiotic control molecule. Content continues below Related Content The phase 2a stage of the clinical trial will study the safety, tolerability and early efficacy of NOV-001 in patients with enteric hyperoxaluria. About GEMMs Genetically engineered microbial medicines (GEMMs) are Novome’s proprietary commensal bacterial strains designed to colonize the gut at a controllable abundance and express therapeutic transgenes and/or proteins at clinically meaningful levels. Colonization is maintained using a daily oral dose of a prebiotic polysaccharide that GEMMs are engineered to depend upon for their survival. About NOV-001 NOV-001 is an investigational combination product composed of NB1000S, a recombinant live biotherapeutic product, and NB2000P, a botanically derived polysaccharide. In the phase 1 stage of the clinical trial, orally-administered NOV-001 was safe and well tolerated and demonstrated dose-dependent strain engraftment in healthy volunteers. Preclinical studies of NOV-001 showed consistent and robust reduction in urine oxalate levels in multiple animal models of disease. Novome believes NOV-001 will enable controlled engraftment of the gut with a microbial strain engineered to efficiently degrade oxalate in the gastrointestinal (GI) tract to decrease the risk of progressive kidney damage and kidney stone formation. About enteric hyperoxaluria Hyperoxaluria is a metabolic disorder characterized by significantly elevated urinary oxalate levels. It is often associated with kidney stones, chronic kidney disease (CKD) and other serious diseases. Content continues below Related Content Enteric hyperoxaluria results from underlying chronic GI disorders, such as bariatric surgery or inflammatory bowel disease, that cause increased absorption of dietary oxalate, which is present in many healthy foods. There are approximately 250,000 patients in the U.S. with enteric hyperoxaluria and there are no FDA-approved therapies. Explore Related Topics:

Novome Biotechnologies Frequently Asked Questions (FAQ)

  • When was Novome Biotechnologies founded?

    Novome Biotechnologies was founded in 2015.

  • Where is Novome Biotechnologies's headquarters?

    Novome Biotechnologies's headquarters is located at 279 E Grand Ave, South San Francisco.

  • What is Novome Biotechnologies's latest funding round?

    Novome Biotechnologies's latest funding round is Series B.

  • How much did Novome Biotechnologies raise?

    Novome Biotechnologies raised a total of $77.04M.

  • Who are the investors of Novome Biotechnologies?

    Investors of Novome Biotechnologies include Alexandria Venture Investments, Alta Partners, 5AM Ventures, DCVC, Tencent Holdings and 7 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.